 Cidara Therapeutics, Inc. CDTX, a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the publication of 10 abstracts reporting new clinical and preclinical data on the Companys antifungal rezafungin program and preclinical data on its Cloudbreak antiviral program. The abstracts are being published by the European Congress of Clinical Microbiology and Infectious Diseases ECCMID in an online book of abstracts that had been accepted for presentations at ECCMID 2020, which was canceled due to the coronavirus global pandemic. 